Incidence and risk of denosumab-related hypocalcemia in cancer patients: A systematic review and pooled analysis of randomized controlled studies

Current Medical Research and Opinion

Volumn 29, Issue 9, 2013, Pages 1067-1073

  Qi, Wei Xiang ^a   Lin, Feng ^a   He, Ai Na ^a   Tang, Li Na ^a   Shen, Zan ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cancer; Denosumab; Hypocalcemia; Meta analysis

Indexed keywords

ANTIANDROGEN; DENOSUMAB;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; DATA ANALYSIS; HUMAN; HYPOCALCEMIA; INCIDENCE; META ANALYSIS; MORBIDITY; PHYSICIAN; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SOLID TUMOR; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; HYPOCALCEMIA; INCIDENCE; MALE; NEOPLASMS; PUBMED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84882759793     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.813840     Document Type: Article

References (38)

1. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
2. Aapro MS. Denosumab for bone metastases from breast cancer: A new therapy optioñJ Clin Oncol 2011;29:e419-20; author reply e21-4
3. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84
4. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
5. Qi WX, Tang LN, He AN, et al. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: A meta-analysis of four randomized controlled trials. Lung 2011;189:437-43
6. Qi WX, Tang LN, He AN, et al. Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: A systematic review and indirect comparison. Curr Med Res Opin 2012;28:643-50
7. Su Y, Yang WB, Li S, et al. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: A meta-analysis of the published literature. PLoS One 2012;7:e35629
8. Qi WX, Shen Z, Lin F, et al. Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: An updated meta-analysis of ten randomized controlled trials. Int J Cancer 2013;132: E66-73
9. Qi WX, Wang Q, Jiang YL, et al. Overall survival benefits for combining targeted therapy as second-line treatment for advanced nonsmall-cell-lung cancer: A meta-analysis of published data. PLoS One 2013;8:e55637
10. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350: 1655-64
11. Theriault RL. Biology of bone metastases. Cancer Control 2012;19:92-101
12. Bundred N. Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev 2012;38:776-86
13. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39-46
14. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28:5132-9
15. Reddy GK, Mughal TI, Roodman GD. Novel approaches in the management of myeloma-related skeletal complications. Support Cancer Ther 2006;4: 15-18
16. Peddi P, Lopez-Olivo MA, Pratt GF, et al. Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis. Cancer Treat Rev 2013;39:97-104
17. Brown-Glaberman U, Stopeck AT. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 2012;6:89-99
18. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006;11:81-8
19. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008;43:222-9
20. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32
21. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377:813-22
22. Khan A, Fong J. Hypocalcemia: Updates in diagnosis and management for primary care. Can Fam Physician 2012;58:158-62
23. NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE). Available at: Http://ctepcancergov/protocolDevelopment/electronic-applications/ctchtm [Last accessed 27 January 2013]
24. Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280-5
25. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-37
26. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71
27. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
28. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361: 745-55
29. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71
30. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-82
31. Shoback D. Hypoparathyroidism. N Engl J Med 2008;359:391-403
32. Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ 2008;336:1298-302
33. Kim BG, Chang SK, Kim SM, et al. Dilated cardiomyopathy in a 2 month-old infant: A severe form of hypocalcemia with vitamin D deficient rickets. Korean Circ J 2010;40:201-3
34. Tomar M, Radhakrishnan S, Shrivastava S. Myocardial dysfunction due to hypocalcemia. Indian Pediatr 2010;47:781-3
35. Gulley JL, Wu S, Arlen PM, et al. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clin Genitourin Cancer 2007;5: 403-5
36. McCormick BB, Davis J, Burns KD. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 2012;60:626-8
37. Mishra A. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient. J Postgrad Med 2008;54:237
38. Segal E, Felder S, Haim N, et al. Vitamin D deficiency in oncology patients - an ignored condition: Impact on hypocalcemia and quality of life. Isr Med Assoc J 2012;14:607-12